USA - NASDAQ:SOLY - Common Stock
The current stock price of SOLY is 22.58 null. In the past month the price increased by 8.66%. In the past year, price increased by 170.42%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 26.06 | 226.31B | ||
| ISRG | INTUITIVE SURGICAL INC | 63.5 | 195.98B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.49 | 150.78B | ||
| SYK | STRYKER CORP | 27.34 | 137.68B | ||
| BDX | BECTON DICKINSON AND CO | 13.24 | 54.74B | ||
| IDXX | IDEXX LABORATORIES INC | 53.05 | 53.52B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.97 | 49.75B | ||
| RMD | RESMED INC | 24.72 | 35.71B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.39 | 32.25B | ||
| PODD | INSULET CORP | 71.78 | 23.09B | ||
| DXCM | DEXCOM INC | 31.45 | 22.94B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.96 | 17.56B |
Soliton, Inc. is a medical development company, which engages in the development of healthcare technological devices for medical and cosmetic treatments. The company is headquartered in Houston, Texas and currently employs 13 full-time employees. The company went IPO on 2019-02-19. The firm is focused on developing and commercializing products utilizing its designed acoustic shockwave technology platform referred to as Rapid Acoustic Pulse (RAP). The company develops products for the removal of tattoos and the reduction of cellulite. The RAP device in coordination with the pulsed laser removes ink pigment from the macrophages. Its RAP device uses pulses of designed acoustic shockwaves to disrupt cellular structures in the dermal and subdermal tissue. It’s designed shockwave allows it to target the stiffness between cellular structures and generate an effect that represents a platform technology in tattoo removal, cellulite treatment, fibrotic scar treatment and other indications. Its technology allows the disruption of targeted structures within the skin with minimal discomfort and without additional treatment-related downtime for tattoo removal or any downtime for cellulite treatment.
Soliton Inc
5304 Ashbrook Dr
Houston TEXAS 77081 US
CEO: Brad Hauser
Employees: 13
Phone: 18326613453.0
Soliton, Inc. is a medical development company, which engages in the development of healthcare technological devices for medical and cosmetic treatments. The company is headquartered in Houston, Texas and currently employs 13 full-time employees. The company went IPO on 2019-02-19. The firm is focused on developing and commercializing products utilizing its designed acoustic shockwave technology platform referred to as Rapid Acoustic Pulse (RAP). The company develops products for the removal of tattoos and the reduction of cellulite. The RAP device in coordination with the pulsed laser removes ink pigment from the macrophages. Its RAP device uses pulses of designed acoustic shockwaves to disrupt cellular structures in the dermal and subdermal tissue. It’s designed shockwave allows it to target the stiffness between cellular structures and generate an effect that represents a platform technology in tattoo removal, cellulite treatment, fibrotic scar treatment and other indications. Its technology allows the disruption of targeted structures within the skin with minimal discomfort and without additional treatment-related downtime for tattoo removal or any downtime for cellulite treatment.
The current stock price of SOLY is 22.58 null. The price increased by 0.13% in the last trading session.
SOLY does not pay a dividend.
SOLY has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
SOLY stock is listed on the Nasdaq exchange.
Soliton Inc (SOLY) has a market capitalization of 485.90M null. This makes SOLY a Small Cap stock.
ChartMill assigns a technical rating of 6 / 10 to SOLY. When comparing the yearly performance of all stocks, SOLY is one of the better performing stocks in the market, outperforming 97.92% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to SOLY. While SOLY has a great health rating, there are worries on its profitability.
Over the last trailing twelve months SOLY reported a non-GAAP Earnings per Share(EPS) of -0.85. The EPS decreased by -18.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -4832.43% | ||
| ROA | -69.93% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
8 analysts have analysed SOLY and the average price target is 23.05 null. This implies a price increase of 2.09% is expected in the next year compared to the current price of 22.58.